Artificial intelligence is rapidly becoming an integral tool in dermatology, offering enhanced diagnostic accuracy, more efficient workflows, and broader access to care. In 2026, practitioners are witnessing AI’s expanding role—from advanced imaging and lesion classification to predictive analytics and virtual triage—while grappling with key challenges such as algorithm bias, regulatory oversight, and data privacy. This session will offer a balanced update on AI’s clinical capabilities, current limitations, and practical considerations for responsibly integrating these tools into daily dermatologic practice.

From AI enhanced diagnostic tools and secure clinical imaging solutions to evolving teledermatology workflows, this session will deliver a dynamic overview of emerging technologies shaping modern dermatologic practice. Attendees will explore not only the latest technical capabilities—such as smartphone-integrated imaging systems, machine learning applications for lesion assessment, and encrypted photo management platforms—but also practical considerations, including privacy compliance and implementation in everyday workflows. The overall goal is to equip clinicians with the knowledge to judiciously adopt tech innovations that will enhance accuracy, efficiency, and patient safety in dermatologic care.

Many systemic and dermatologic conditions manifest eye-related symptoms that can offer early warning signs—making basic ophthalmologic awareness invaluable for dermatologists. This session will review essential ocular anatomy, common ocular presentations linked to skin and systemic pathology, and practical assessment techniques suitable for real-world clinical settings. Attendees will learn when initial evaluation and timely referral are warranted, empowering them to incorporate eye care insights into more comprehensive patient management.

The connection between inflammatory bowel disease (IBD) and dermatologic conditions is increasingly recognized, with skin findings often reflecting underlying intestinal inflammation or therapy-related effects. This session will highlight the spectrum of cutaneous manifestations that may accompany IBD, and the importance of timely recognition and management. Attendees will gain practical strategies for identifying dermatologic signs that may signal gastrointestinal disease, as well as approaches for effective collaboration with gastroenterology specialists.

Many systemic diseases with cutaneous manifestations also present with characteristic ocular findings, providing dermatologists with an additional lens for early recognition. This session will examine how conditions such as lupus, dermatomyositis, sarcoidosis, and other autoimmune or inflammatory dermatoses reveal themselves through ocular changes, including dryness, conjunctival inflammation, uveitis, or retinal abnormalities. Attendees will learn practical strategies for identifying these signs during dermatologic evaluation, appreciating their implications for systemic disease management, and understanding when referral to ophthalmology is warranted.

Vulvar dermatoses are often misdiagnosed or overlooked, making clinical acumen and patient-centered strategies especially vital. This session will offer practical pearls for effective history-taking and examination—emphasizing techniques like differentiating itch versus pain, conducting a systematic exam with patient comfort, and using oriented biopsy methods. Attendees will learn how to enhance diagnostic accuracy, improve communication, and optimize treatment adherence, with the goal of equipping dermatologists with actionable, empathetic tools to elevate care in the often underrecognized field of vulvar dermatology.

These highly interactive educational sessions offer a comprehensive and practical look into a diverse array of dermatologic conditions. With a focus on translating current research into practical, real-world applications, these sessions will help you to effectively integrate the latest advances in dermatologic care into clinical practice, enhancing your professional skills and improving patient outcomes. Both seasoned and early-career dermatology professionals will benefit from these educational grant–supported sessions.

Applications for commercial support from healthcare-related industries are pending. Commercial support will be acknowledged as it is received.

Seborrheic dermatitis is a chronic, relapsing inflammatory skin condition that disproportionately affects sebaceous gland-rich areas and poses treatment challenges for many patients. Advances in understanding its underlying immune and microbiome mechanisms are driving the development of newer, more convenient topical options alongside optimized use of traditional therapies. This session will offer practical guidance on individualizing treatment regimens—spanning antifungals, anti-inflammatory agents, and procedural tools—in a way that balances efficacy, safety, and patient adherence.

Serologic evaluation plays a pivotal role in diagnosing and monitoring autoimmune diseases in dermatology, but tests must be ordered judiciously to inform care without causing confusion or unnecessary intervention. This session will outline the dermatologist’s framework for selecting and interpreting autoimmune serologies, emphasizing clinical context, pre-test probability, and collaboration with rheumatology colleagues. Attendees will learn to distinguish between supportive versus diagnostic value, manage uncertainty, and align testing strategies with evolving guideline-driven algorithms.

Prescribing in pregnancy requires a careful balance between managing maternal conditions and ensuring fetal safety. This session will focus on evidence-informed approaches to evaluating and prescribing dermatologic therapeutics during pregnancy and lactation, emphasizing comprehensive medication review, pharmacokinetic changes in pregnancy, and shared decision-making with patients. Attendees will explore strategies to assess risk, prioritize safer topical options when possible, and thoughtfully integrate systemic therapies when necessary.

Prescription drug costs remain a major challenge, shaped by a complex mix of development expenses, market exclusivity, supply chain dynamics, and the growing use of advanced therapies. These pressures continue to strain healthcare budgets and patient access, while policymakers explore strategies to curb rising expenditures. This session will provide an overview of the key factors driving costs, highlight the evolving policy landscape, and consider the implications for clinicians, healthcare systems, and the dermatology patients they serve.

Identifying high risk pregnancies is essential to ensuring timely, specialized care and optimizing outcomes for both patient and fetus. This session will outline key clinical criteria—such as pre existing conditions, pregnancy-related complications, advanced maternal age, multiple gestation, and fetal concerns—that may warrant consultation with a maternal fetal medicine (MFM) specialist. Attendees can expect guidance on risk assessment strategies, referral timing, and effective coordination with MFM teams to facilitate personalized care planning.

The healthcare reimbursement environment continues to evolve as payers adjust policies in response to economic pressures and shifting models of care. This session will provide an overview of anticipated changes in payment structures, highlighting how these developments may affect practice operations, provider revenue, and patient access. Attendees will gain practical strategies for adapting to these adjustments, including approaches to documentation, compliance, and integration of value-based care principles.

Chronic lichen planus and related lichenoid dermatoses often pose therapeutic challenges, especially in persistent or treatment-resistant cases. This session will explore both foundational approaches—such as topical and systemic corticosteroids, phototherapy, and immune-modulating agents—and emerging, pathogenesis-driven treatments like JAK inhibitors, PDE 4 inhibitors, and biologics targeting IL 17/IL 23 pathways. Attendees will gain insight into when to escalate care, how to individualize treatment based on disease subtype or severity, and where novel therapies are showing promise in clinical practice.

As inflammatory bowel disease (IBD) management evolves, combination therapy—using multiple agents targeting distinct immune pathways—is emerging as a way to overcome treatment resistance and better control complex disease patterns. Dermatologists can draw inspiration from this model to address challenging cases in dermatologic inflammatory conditions. This session will guide clinicians in thoughtfully applying multi-modal treatment principles, focusing on patient selection, balancing efficacy with safety, and coordinating cross-specialty care.

These highly interactive educational sessions offer a comprehensive and practical look into a diverse array of dermatologic conditions. With a focus on translating current research into practical, real-world applications, these sessions will help you to effectively integrate the latest advances in dermatologic care into clinical practice, enhancing your professional skills and improving patient outcomes. Both seasoned and early-career dermatology professionals will benefit from these educational grant–supported sessions.

Applications for commercial support from healthcare-related industries are pending. Commercial support will be acknowledged as it is received.

Following Mohs micrographic surgery—especially in sensitive or complex locations—reconstructive collaboration becomes essential to restore anatomy and function while preserving aesthetics. This session will highlight the critical role of plastic surgeons in planning and executing reconstructive options that complement Mohs techniques, such as flap design, grafting, and wound healing approaches. Discussion topics will include multidisciplinary decision-making principles, technical considerations for reconstruction, and strategies to optimize both patient-centered and oncologic outcomes.

Systemic sclerosis (SSc) remains a high mortality connective tissue disease with limited disease modifying therapies and significant clinical heterogeneity. This session will spotlight advances in targeted and regenerative treatments—ranging from precision based immunomodulatory agents that disrupt inflammatory and fibrotic pathways to stem cell-based strategies aimed at restoring tissue integrity. Attendees will explore how evolving molecular insights and early clinical innovations are ushering in a shift from reactive management toward proactive, personalized approaches in SSc care.

Psoriatic arthritis is a frequently underdiagnosed comorbidity in patients with psoriasis, yet timely recognition and intervention are critical to preserving function and quality of life. Dermatologists are uniquely positioned to identify early signs and symptoms, integrate screening into routine practice, and collaborate across specialties to ensure comprehensive care. This session will provide practical strategies to help clinicians confidently recognize psoriatic arthritis, initiate appropriate management, and improve outcomes through proactive, patient-centered approaches.

Dermatologists frequently encounter manifestations of allergic diseases that overlap with skin presentations, necessitating a solid foundation in allergy fundamentals. This session will guide clinicians through recognizing key signs of allergic involvement—from contact reactions to urticaria and atopic inflammation—while also clarifying when to manage in-house and when specialty referral is warranted. Attendees will gain an understanding of the dermatologist’s role in diagnosis and initial intervention, as well as frameworks for effective collaboration with allergists to optimize patient outcomes.

Dermatomyositis (DM) poses significant diagnostic and therapeutic challenges due to its dual skin and muscle involvement, variable clinical subtypes, and high-risk complications like interstitial lung disease and malignancy. This session will present the latest advances from a dermatologic lens, including targeted treatments that inhibit specific immune pathways, and promising results with JAK inhibitors in refractory cutaneous disease. Attendees will also explore the evolving landscape of outcome measures tailored to skin-predominant DM, enhancing both clinical trial design and real-world assessment of therapeutic response.

The understanding of immune-mediated hair loss is advancing quickly, with new insights into disease mechanisms opening the door to innovative treatment strategies. Emerging therapies are moving beyond traditional approaches, offering the potential for more targeted, personalized care in conditions that have historically been difficult to manage. This session will highlight evolving trends in both diagnostics and treatment, providing dermatologists with practical knowledge to better address complex hair loss disorders.

Contact dermatitis remains a common and clinically significant concern in dermatology, driven by evolving exposure patterns and a diverse range of allergens and irritants. This session will delve into updated approaches for accurate diagnosis—including thoughtful clinical assessment and refined patch-testing strategies—and effective management that balances avoidance, topical therapies, and patient education. Attendees will learn how to recognize emerging allergens and patterns of sensitization, apply tailored diagnostic tools, and deliver care that is both thorough and practical.

These highly interactive educational sessions offer a comprehensive and practical look into a diverse array of dermatologic conditions. With a focus on translating current research into practical, real-world applications, these sessions will help you to effectively integrate the latest advances in dermatologic care into clinical practice, enhancing your professional skills and improving patient outcomes. Both seasoned and early-career dermatology professionals will benefit from these educational grant–supported sessions.

Applications for commercial support from healthcare-related industries are pending. Commercial support will be acknowledged as it is received.

Recent developments in vitiligo treatment are offering fresh hope for patients and clinicians alike by expanding beyond traditional approaches like phototherapy and corticosteroids. Emerging strategies—including advanced topical formulations, immune-targeted therapies, and novel regenerative approaches—are showing promising results in stimulating repigmentation with enhanced safety and personalization. This session will explore the evolving therapeutic landscape while addressing the emotional and psychosocial burdens of vitiligo, enabling dermatologists to offer more comprehensive, patient-centered care.

Hyperpigmentation—stemming from factors like sun exposure, inflammation, or skin injury—is among the most common concerns seen in dermatology, particularly pronounced in patients with richly pigmented skin. Effective management requires a thoughtful, layered strategy that may include diligent photoprotection, considerate use of topical lightening agents, and careful selection of in-office procedures when needed. This session will present a balanced approach, weighing efficacy and safety while emphasizing prevention, evidence-informed use of topical and procedural tools, and personalized guidance to optimize outcomes.

Innovative therapies are reshaping the management of bullous disorders. Advances in genetic approaches are opening new possibilities for improving wound healing and skin function in patients with historically limited options. At the same time, targeted immune-based treatments are providing safer and more effective alternatives to traditional broad immunosuppression. This session will highlight these evolving strategies and their impact on patient-centered care, equipping clinicians with the latest insights into the future of treating severe blistering skin diseases.

Embarking on clinical trial research offers dermatologists a powerful path to contribute to therapeutic advances, but requires careful navigation of regulatory, ethical, and operational hurdles. This session will demystify the process by outlining essential steps—from conceptualizing the research question and designing protocols to navigating IRB approval, adhering to Good Clinical Practice standards, and managing trial logistics effectively. Attendees will learn how to build trial infrastructure, ensure data integrity, and foster participant engagement, empowering them to lead or collaborate in meaningful studies with confidence and scientific rigor.

Patients with a history of organ transplantation face dramatically elevated risks for aggressive skin cancers, demanding vigilant, proactive dermatologic oversight. This session will outline key risk factors—such as the type and duration of immunosuppression, transplant category, past skin damage, and demographic predispositions—and emphasize effective surveillance strategies, including risk stratification, regular full-body exams, and collaborative care frameworks. Attendees will learn how to integrate chemopreventive approaches, tailored sun protection guidance, and early interventional treatment into practice to reduce morbidity and improve long-term outcomes.

These highly interactive educational sessions offer a comprehensive and practical look into a diverse array of dermatologic conditions. With a focus on translating current research into practical, real-world applications, these sessions will help you to effectively integrate the latest advances in dermatologic care into clinical practice, enhancing your professional skills and improving patient outcomes. Both seasoned and early-career dermatology professionals will benefit from these educational grant–supported sessions.

Applications for commercial support from healthcare-related industries are pending. Commercial support will be acknowledged as it is received.

Despite growing awareness, outcome-measure frameworks in dermatology frequently overlook the nuanced needs of patients with diverse skin tones and other underrepresented groups, risking biased assessments and inequitable treatment decisions. Emphasizing inclusive research methodologies and consensus-driven tools, this panel aims to broaden the relevance and accuracy of dermatologic outcome measures. Attendees will gain an understanding of strategies to integrate a wide range of skin types and perspectives into the development of patient-centered outcome instruments, ensuring validity across populations.

Biologics and small-molecule inhibitors have transformed treatment options for many inflammatory dermatologic conditions—but they also raise important questions about appropriate screening and monitoring. This session will offer evidence-informed guidance on when to conduct baseline tests and how to tailor ongoing surveillance based on agent-specific risk profiles and patient comorbidities. Attendees will learn about real-world practice patterns, variability in monitoring, and practical strategies to optimize both safety and resource use.

Hair and scalp concerns—especially those linked to styling practices and unique dermatologic conditions—are among the most frequent yet under-addressed issues in patients with richly pigmented skin. This session will explore how high-tension hairstyles, hair product use, and cultural hair care routines intersect with conditions like scarring alopecia and seborrheic dermatitis, often contributing to inflammatory scalp changes. Clinicians will be guided through culturally competent diagnostic steps, from history-taking that respects hairstyling practices to biopsy when needed, and learn evidence-informed strategies that combine dermatologic safety with patient preferences.

Handheld and high-frequency ultrasound devices are expanding their role in cosmetic dermatology, offering real-time, noninvasive insights into skin structure, product placement, and treatment outcomes. These imaging tools enable dermatologists to identify cosmetic fillers, evaluate complications such as nodules or vascular occlusion, and guide interventions like filler revision with increased precision and safety. This session will equip clinicians with practical knowledge of ultrasound technologies and implementation strategies to enhance safety, efficacy, and patient satisfaction.

Integrating aesthetic-enhancing products into the management of medical skin conditions offers new opportunities to support both health and confidence. This session will examine how carefully selected cosmetic formulations—including cleansers, moisturizers, sunscreens, and non-comedogenic products—can safely complement medical treatments to improve outcomes and patient wellbeing. Attendees will learn practical strategies for advising patients on choosing and incorporating cosmetics that support skin barrier function, reduce irritation, and bolster adherence to therapeutic regimens.

Advances in biologics, small molecules, and immunotherapies are steadily reshaping the therapeutic landscape of psoriasis (PsO), atopic dermatitis (AD), and hidradenitis suppurativa (HS)—bringing remission into clearer view. This session will explore the translational journey from bench to bedside, highlighting how cytokine-targeted agents, innovative modalities, and microbiome-focused approaches are extending disease control and potentially achieving durable remission. Through a discussion of emerging therapies, mechanistic insights, and clinical trial trajectories, attendees will gain a forward-looking perspective on whether remission across these complex inflammatory skin disorders will become a practical reality in 2026.

These highly interactive educational sessions offer a comprehensive and practical look into a diverse array of dermatologic conditions. With a focus on translating current research into practical, real-world applications, these sessions will help you to effectively integrate the latest advances in dermatologic care into clinical practice, enhancing your professional skills and improving patient outcomes. Both seasoned and early-career dermatology professionals will benefit from these educational grant–supported sessions.

Applications for commercial support from healthcare-related industries are pending. Commercial support will be acknowledged as it is received.

These highly interactive educational sessions offer a comprehensive and practical look into a diverse array of dermatologic conditions. With a focus on translating current research into practical, real-world applications, these sessions will help you to effectively integrate the latest advances in dermatologic care into clinical practice, enhancing your professional skills and improving patient outcomes. Both seasoned and early-career dermatology professionals will benefit from these educational grant–supported sessions.

Applications for commercial support from healthcare-related industries are pending. Commercial support will be acknowledged as it is received.

Cutaneous T cell lymphoma (CTCL) presents as a rare yet complex group of T cell malignancies that frequently challenge conventional treatment approaches. This session will guide clinicians through the evolving landscape of CTCL management—highlighting the role of skin-directed therapies alongside novel systemic and immunologic agents, including recently approved immunotherapies and promising investigational treatments. Emphasis will be placed on multidisciplinary, personalized strategies that balance efficacy, safety, and patient-centered care, while anticipating future therapeutic innovations.

Immune checkpoint inhibitors are transforming oncology—but their high rate of cutaneous immune-related adverse events (cirAEs) poses both diagnostic and management challenges for clinicians. This session will explore the diverse spectrum of skin toxicities—from common maculopapular rashes and lichenoid eruptions to rare but serious reactions like Stevens–Johnson syndrome—that can be associated with cancer immunotherapy. Attendees will also be provided with practical guidelines for early recognition, grading, and treatment to ensure continuation of life-saving therapies whenever possible.

Epidermal growth factor receptor (EGFR) inhibitors are cornerstone treatments in oncology, but they are also frequently accompanied by challenging dermatologic side effects—including acneiform eruptions, xerosis, pruritus, paronychia, and hair changes—that impair quality of life and may disrupt cancer therapy. This session will discuss proactive strategies—such as early patient education, gentle skincare regimens, sun protection, and prophylactic tetracyclines—to reduce severity and preserve adherence to cancer treatments. Attendees will also receive guidance on collaboration with oncology teams for seamless care delivery.